March 3, 2026Open Access

Cost Consequences Associated With Biologic Therapy Switching in Publicly Insured Psoriasis Individuals in the United States

Key Points

Switching biologic therapy is associated with significant cost consequences for publicly insured individuals with psoriasis.
The analysis indicates that financial implications may vary based on specific treatment regimens.
Assessment utilized data from Merative Marketscan to evaluate cost impacts related to therapy switching.
Understanding these consequences is vital for healthcare planning and budget allocation in psoriasis treatment.

Abstract

Q.W.S. has no potential competing interests to disclose. J.M.C. serves on a data and safety monitoring board (DSMB) for Advarra and has served as a consultant for Novartis, Takeda, GSK, and Sanofi. W.E.D. has served as a consultant for Priovant Therapeutics, Pfizer, Eli Lilly, TWI Biotechnology, Fresenius Kabi, Epiarx Diagnostics, Incyte, Boehringer Ingelheim, CSL Behring, AbbVie, Sanofi, and Bain Capital Life Sciences; has been provided research support from Pfizer, Advanced Cell Diagnostics/Bio-Techne, AbbVie, Bristol Myers Squibb; and receives licensing fees from EMD/Millipore/Sigma. The data that support the findings of this study are available from Merative Marketscan. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from https://www.merative.com/documents/merative-marketscan-research-databases with the permission of Merative Marketscan.

Cost Consequences Associated With Biologic Therapy Switching in Publicly Insured Psoriasis Individuals in the United States

Key Points

Abstract

Cite This Study